AstraZeneca

AstraZeneca to Invest $50 Billion in US Manufacturing

AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.

AstraZeneca to Establish Global Drug Research Center in Beijing

Britain’s AstraZeneca wants to invest $2.5 billion in Beijing, China to establish its sixth global strategic R&D center.

FibroGen Sells Chinese Subsidiary to AstraZeneca

US-based biotechnology company FibroGen announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.

AstraZeneca Plans $570 Million Investment in Canada

To support the move to a larger office facility in the Greater Toronto Area, Ontario, AstraZeneca plans to invest $570 million in Canada, creating more than 700 jobs.

AstraZeneca to Invest $3.5 Billion in the US

Anglo-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the US to expand the company’s research and manufacturing footprint by the end of 2026.

AstraZeneca to Build $1.5 Billion ADC Production Facility in Singapore

In a move to enhance global supply of its antibody drug conjugates (ADCs) portfolio, AstraZeneca intends to build a $1.5 billion facility in Singapore for the manufacturing of ADCs.

AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4 Billion

AstraZeneca has agreed to acquire Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

AstraZeneca to Buy Amolyt Pharma for up to $1.05 Billion

Britain's AstraZeneca is to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases, more than $1 billion.

AstraZeneca Plans £650 Million Investment in UK

AstraZeneca, whose CEO Pascal Soriot has been critical of the UK business environment for the life sciences industry in the past, wants to invest a large sum at its homebase. On Mar. 6, Chancellor Jeremy Hunt announced that the pharma giant plans to invest £650 million in the UK.

AstraZeneca Completes Acquisitions of Gracell and Icosavax

Within a few days, Anglo-Swedish drugmaker AstraZeneca has completed the acquisitions of Gracell Biotechnologies and Icosavax. Both transactions were announced in December 2023.

AstraZeneca to Construct New US Cell Therapy Facility

In a move to launch its cell therapy platforms for critical cancer trials in the US, AstraZeneca is investing $300 million in a new facility in Rockville, Maryland. The site will initially focus on the production of T-cell therapies, with the possibility of supporting other disease areas in the future.

AstraZeneca to Buy Cell Therapy Developer Gracell for Up to $1.2 Billion

AstraZeneca has agreed to acquire Gracell Biotechnologies, a Chinese developer of cell therapies for the treatment of cancer and autoimmune diseases, for up to $1.2 billion. Only on Dec. 12, 2023, AstraZeneca announced that it was planning to acquire Icosavax for $1.2 billion.

AstraZeneca to Buy Vaccine Company Icosavax for $1.1 Billion

AstraZeneca has entered into an agreement to acquire Icosavax, a US biopharmaceutical company based in Seattle in a deal worth up to $1.1 billion. The company focuses on the development of differentiated vaccines with high potential using an innovative virus-like protein (VLP) particle platform.

AstraZeneca Invests $245 Million in French Biotech Cellectis

Anglo-Swedish drugmaker AstraZeneca entered into a collaboration and investment agreement with Cellectis, a French clinical-stage biotechnology company, to accelerate the development of therapeutics across oncology, immunology and rare diseases.

AstraZeneca Granted Global Starmap AI License for Nanoform

Nanoform, a nanoparticle medical technology company, has awarded AstraZeneca a global online STARMAP license. STARMAP is an AI-based digital rendition of CESS technology, facilitating in-silico experiments for selecting molecules to be nanoformed. This license enables AstraZeneca to screen molecules during the entire drug development process.

AstraZeneca, SAS Team up on AI and Analytics in Clinical Trials

AI and analytics software company SAS is collaborating with global biopharmaceutical company AstraZeneca to increase efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

AstraZeneca Acquires Early-stage Gene Therapies from Pfizer

Alexion, AstraZeneca's rare disease division, has agreed to buy a portfolio of preclinical gene therapy programs and enabling technologies from competitor Pfizer for up to $1 billion, plus tiered royalties on sales.

AstraZeneca Buys CinCor Pharma

AstraZeneca has entered into an agreement to buy CinCor Pharma, a US-based clinical-stage biopharma focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

AstraZeneca Boosts Cancer Portfolio with Neogene Buy

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and manufacture of next-generation T-cell receptor therapies (TCR-Ts) – a promising and novel cell therapy approach to target cancer.

AstraZeneca Withdraws US Vaxzevria Launch Plan

AstraZeneca (AZ) has announced it is permanently backing away from any plans to sell its Vaxzevria-branded Covid-19 vaccine in the US.

AstraZeneca CEO Goes “Off Message” on Covid Boosters

Days before the FDA approved the new bivalent Covid-19 vaccine boosters, Pascal Soriot, CEO of AstraZeneca, offered his own assessment of the need for such.

AstraZeneca and Ionis Collaborate on TTR Amyloidosis

AstraZeneca and Ionis Pharmaceuticals have finalized their agreement to develop and commercialize investigational therapy eplontersen, formerly known as Ionis-TTR-L. The companies previously announced their intention to collaborate on Dec. 7, 2021.

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

AstraZeneca’s Alexion Buys Caelum Biosciences

AstraZeneca’s rare diseases unit Alexion has taken full control of Caelum Biosciences, gaining access to another rare disease drug, CAEL-101, which is a potential treatment for light chain amyloidosis (AL) that has been granted Fast Track status by the US Food and Drug Administration (FDA).

AstraZeneca Shows FDA Enouraging Antiviral Data

AstraZeneca has provided the US Food and Drug Administration (FDA) with encouraging study evidence that its antiviral cocktail candidate AZD7442 can prevent Covid-19 infections in vulnerable people, such as those who are unlikely to respond well to vaccines. This followed disappointing results from an earlier study.

AstraZeneca to Build API Plant in Ireland

AstraZeneca is building what it said is a “next-generation” active pharmaceutical ingredient (API) manufacturing plant for small molecules near Dublin, Ireland. A start-up date was not announced for the new facility that will be the Anglo-Swedish drugmaker’s first investment in the country.

Regeneron and AstraZeneca in Obesity Partnership

US biotech Regeneron is collaborating with AstraZeneca to research, develop and commercialize small molecule medicines targeting GPR75 for treating obesity.

UK Greenlights AstraZeneca/Alexion Deal

The bark of the UK’s Competition and Markets Authority (CMA) evidently is worse than its bite – which in the case of AstraZeneca’s $39 billion acquisition of Alexion was none at all. Only a week after European authorities approved the deal, the CMA also gave the green light, without voicing any competition concerns. With this behind it, the two drugmakers are free to merge by Jul. 21.

EU Approves AstraZeneca Takeover of Alexion

EU competition authorities have approved AstraZeneca’s $39 billion takeover of US biopharma Alexion. Europe’s green light for the deal sealed in December 2020 follows the approval of the US Federal Trade Commission (FTC) in April 2021.

Denmark’s AstraZeneca Vaccine Doses up for Grabs

Denmark has taken what it said was a final decision to discontinue using the AstraZeneca Covid-19 vaccine in its national inoculation campaign after an unusual string of rare blood clots. A discussion has begun over what to do with the remaining supply.

AstraZeneca’s Vaccine Update Shows Efficacy Change

AstraZeneca has released an updated statement on the efficacy of its Covid-19 vaccine after US health authorities criticized its analysis of US Phase 3 trial results as confusing and suggested that the company might be combining results from different phases.

AstraZeneca and US Trial Board at Odds

The AstraZeneca Covid vaccine’s brief respite from global negative headlines achieved after it published positive results from its US clinical trial on Mar. 22 was even briefer than usual. Soon after publication, the figures were criticized by the trial’s independent data safety monitoring board (DSMB), a move experts called unprecedented or at least highly unusual. The drugmaker promised to publish more information within 48 hours.

AstraZeneca Sees 79% Efficacy in US Vaccine Trial

Preliminary results from AstraZeneca’s recently completed US Phase 3 trial showed its Covid-19 vaccine to be 79% effective against symptomatic forms of the disease, along with offering 100% protection against severe disease, hospitalization and death, the company revealed on Mar. 22. In participants over 65, efficacy was even higher at 80%.

WHO Grants EUA for AstraZeneca Vaccine

The World Health Organization (WHO) has granted emergency use authorization (EUA) to the AstraZeneca/ Oxford University coronavirus vaccine, in an attempt to distribute doses to more Third World countries. The vaccine will be produced by the Serum Institute of India and AstraZeneca-SKBio of South Korea.

EMA Greenlights AstraZeneca Covid Vaccine

As expected, the Europe Medicines Agency (EMA) on Jan. 29 gave the green light for AstraZeneca’s Covid-19 vaccine for use in the Covid-19 vaccine for use in the 27-member EU. Rather than this news, however, the political fallout over the bloc’s response to the drugmaker’s delivery delays announced at the beginning of the week continued to dominate the conversation.

AstraZeneca Covid Vaccine Shows 70% Efficacy

AstraZeneca’s viral vector vaccine candidate for Covid-19, AZD1222, moved back into the spotlight again this week after giving up headlines recently to the mRNA candidates of Pfizer-BioNTech and Moderna.

AstraZeneca US Vaccine Trial to Resume

AstraZeneca’s paused Phase 3 US clinical trial with its Covid-19 adenovirus vaccine candidate could resume as early as this week, sources have told both Reuters and the Wall Street Journal. The drugmaker initially paused all global trials in early September, after a participant in the UK Phase 3 test suffered a spinal inflammatory disorder. The purported diagnosis of transverse myelitis was never officially confirmed.

Samsung Super Plant to Supply AstraZeneca

Korean CMO Samsung Biologics has signed on with AstraZeneca to support the UK drugmaker’s biologics therapeutics. The company will produce bulk drug substance and drug product for its customer at its new $2 billion Plant 3 facility in Incheon, South Korea, set to go on stream in 2022.

AstraZeneca US Vaccine Trial in Limbo

The US Food and Drug Administration (FDA) is deliberating whether to allow AstraZeneca to resume its recently begun Phase 3 US clinical trial of the adenovirus-based Covid-19 vaccine it is developing for Oxford University. An adverse event last week caused the – meanwhile resumed – UK study to be paused,

AstraZeneca Resumes UK Covid Vaccine Trials

AstraZeneca has resumed Phase 2/3 clinical trials with Oxford University’s Covid-19 vaccine candidate in the UK, days after halting the tests due to an “adverse neurological event” that CEO Pascal Soriot said occurred in the UK trial and involved an inflammatory spinal cord disorder.

Catalent in new Vaccine Production Deal with AstraZeneca

Catalent Cell & Gene Therapy, a unit of US-based CDMO Catalent, has signed on to provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine candidate, known as AZD1222. Financial details were not disclosed.

Australia Inks Vaccine Deal with AstraZeneca

The government of Australia has sealed a deal with AstraZeneca to supply enough doses of the adenovirus vector-based vaccine being developed on behalf of Oxford University to inoculate 95% of the country’s entire population of 25 million. The two sides have signed a Letter of Intentm but details on how the ambitious vaccination plan would be financed have not been revealed.

AstraZeneca Licenses Covid Candidate to China

In a much heeded licensing deal, AstraZeneca (AZ) has awarded Chinese pharma BioKangta sole commercial rights to its AZD1222 Covid-19 vaccine candidate in the People’s Republic. The UK drugmaker is developing the adenovirus vector-based vaccine on behalf of Oxford University, which created it.

AstraZeneca and Daiichi Sankyo in Cancer Drug Deal

UK-Swedish drugmaker AstraZeneca has entered into a global development and commercialization agreement with Daiichi Sankyo, which could be worth up to $6 billion for the Japanese pharma.

AstraZeneca Said Weighing Gilead Merger

US Gives AstraZeneca $ 1 billion for Oxford Vaccine

AstraZeneca Targets 30 Million Vaccine Doses by September

AstraZeneca Links with Silence Therapeutics

AstraZeneca Aims to be Carbon Neutral by 2025

AstraZeneca Gives Up on Targacept Antidepressant

Here To Stay